Abstract:BACKGROUND:Identifying cancer subtypes is an important component of the personalised medicine framework. An increasing number of computational methods have been developed to identify cancer subtypes. However, existing methods rarely use information from gene regulatory networks to facilitate the subtype identification. It is widely accepted that gene regulatory networks play crucial roles in understanding the mechanisms of diseases. Different cancer subtypes are likely caused by different regulatory mechanisms. Therefore, there are great opportunities for developing methods that can utilise network information in identifying cancer subtypes.RESULTS:In this paper, we propose a method, weighted similarity network fusion (WSNF), to utilise the information in the complex miRNA-TF-mRNA regulatory network in identifying cancer subtypes. We firstly build the regulatory network where the nodes represent the features, i.e. the microRNAs (miRNAs), transcription factors (TFs) and messenger RNAs (mRNAs) and the edges indicate the interactions between the features. The interactions are retrieved from various interatomic databases. We then use the network information and the expression data of the miRNAs, TFs and mRNAs to calculate the weight of the features, representing the level of importance of the features. The feature weight is then integrated into a network fusion approach to cluster the samples (patients) and thus to identify cancer subtypes. We applied our method to the TCGA breast invasive carcinoma (BRCA) and glioblastoma multiforme (GBM) datasets. The experimental results show that WSNF performs better than the other commonly used computational methods, and the information from miRNA-TF-mRNA regulatory network contributes to the performance improvement. The WSNF method successfully identified five breast cancer subtypes and three GBM subtypes which show significantly different survival patterns. We observed that the expression patterns of the features in some miRNA-TF-mRNA sub-networks vary across different identified subtypes. In addition, pathway enrichment analyses show that the top pathways involving the most differentially expressed genes in each of the identified subtypes are different. The results would provide valuable information for understanding the mechanisms characterising different cancer subtypes and assist the design of treatment therapies. All datasets and the R scripts to reproduce the results are available online at the website: http://nugget.unisa.edu.au/Thuc/cancersubtypes/.

Robust clustering of noisy high-dimensional gene expression data for patients subtyping

Robust correlation estimation and UMAP assisted topological analysis of omics data for disease subtyping

Unraveling the hidden heterogeneities of breast cancer based on functional miRNA cluster.

Robust model-based clustering with gene ranking

Using feature selection and Bayesian network identify cancer subtypes based on proteomic data

Outcome-guided Bayesian clustering for disease subtype discovery using high-dimensional transcriptomic data

Kernel Fusion Method for Detecting Cancer Subtypes via Selecting Relevant Expression Data.

Subtype Dependent Biomarker Identification and Tumor Classification from Gene Expression Profiles.

Clustering cancer gene expression data: a comparative study

UMAP guided topological analysis of transcriptomic data for cancer subtyping

Identifying cancer subtypes in glioblastoma by combining genomic, transcriptomic and epigenomic data

Cancer Subtype Discovery and Biomarker Identification Via a New Robust Network Clustering Algorithm.

Effective cancer subtyping by employing density peaks clustering by using gene expression microarray

Supervised Graph Clustering for Cancer Subtyping Based on Survival Analysis and Integration of Multi-Omic Tumor Data

COPS: A novel platform for multi-omic disease subtype discovery via robust multi-objective evaluation of clustering algorithms

Identifying Cancer Subtypes from Mirna-Tf-mrna Regulatory Networks and Expression Data.

Improvement of Cancer Subtype Prediction by Incorporating Transcriptome Expression Data and Heterogeneous Biological Networks.

Heterogeneous Gene Expression Cross-Evaluation of Robust Biomarkers Using Machine Learning Techniques Applied to Lung Cancer

Outcome-guided Sparse K-means for Disease Subtype Discovery via Integrating Phenotypic Data with High-dimensional Transcriptomic Data

Outcome-Guided Disease Subtyping for High-Dimensional Omics Data

Robust structured heterogeneity analysis approach for high-dimensional data